Nanyang Biologics, a Singapore-based artificial intelligence drug discovery start-up, plans to list on the Nasdaq stock exchange in the first quarter of 2026 via a merger with a US-listed special-purpose acquisition company (SPAC), as US President Donald Trump vowed to impose hefty tariffs on pharmaceutical imports. "The US administration wants intellectual property owners to manufacture in the US, including drugs," founder Roland Ong said on Monday. Nanyang Biologic's latest initiative reflects its effo ...

Core Insights - Amgen Inc is a leading biopharmaceutical company focused on research and development of medicines for various diseases, including inflammation, rare diseases, and cardiovascular diseases [1] Company Overview - Amgen operates globally, emphasizing its commitment to developing innovative therapies [1] Investment Perspective - The company aims to provide long-term returns for investors through its focus on fundamental analysis of dividend and growth equities across diverse sectors [1]

Core Insights - BioCryst Pharmaceuticals (BCRX) is recognized for its leadership in crystallography and structure-based drug design, focusing on novel therapeutics for cancer, cardiovascular diseases, autoimmune diseases, and viral infections [1] - The company has a Zacks Rank of 1 (Strong Buy) and has seen its earnings estimate for the next year increase by 83.3% over the past 60 days [1] - Over the last three months, BioCryst Pharmaceuticals' shares have increased by 39%, significantly outperforming the S&P 500, which gained only 2.2% [2] - The company holds a Momentum Score of B, indicating strong momentum characteristics [2]